Effects of remote haemodynamic‐guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS‐HF study
Authors:
- Birgit AssmusBABirgit Assmus
- Christiane E. AngermannCAChristiane E. Angermann
- Folkert W. AsselbergsFAFolkert W. Asselbergs
- Jasper J. BrugtsJBJasper J. Brugts
- Peter NordbeckPNPeter Nordbeck
- Qian ZhouQZQian Zhou
- Marie‐Elena BrettMBMarie‐Elena Brett
- Philip B. AdamsonPAPhilip B. Adamson
- Michael BöhmMBMichael Böhm
Open Access
- 3 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (12) , 2320-2330
Abstract
Aim: The CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) investigated safety and efficacy of pulmonary artery pressure (PAP)‐guided remote patient management (RPM) in New York Heart Association (NYHA) class III outpatients with at least one heart failure hospitalization (HFH) during the previous 12 months. This pre‐specified subgroup analysis investigated whether RPM effects depended on presence and subtype of pulmonary hypertension (PH). Methods and results: In 106/234 MEMS‐HF participants, Swan–Ganz catheter tracings obtained during sensor implant were available for off‐line manual analysis jointly performed by two experts. Patients were classified into subgroups according to current PH definitions. Isolated post‐capillary PH (IpcPH) and combined post‐ and pre‐capillary PH (CpcPH) were present in 38 and 36 patients, respectively, whereas 31 patients had no PH. Clinical characteristics were comparable between subgroups, but among patients with PH pulmonary vascular resistance was higher ( p = 0.029) and pulmonary artery compliance lower ( p = 0.003) in patients with CpcPH. During 12 months of PAP‐guided RPM, all PAPs declined in IpcPH and CpcPH subgroups (all p < 0.05), whereas only mean and diastolic PAP decreased in patients without PH (both p < 0.05). Improvements in post‐ versus pre‐implant HFH rates were similar in CpcPH (0.639 events/patient‐year; hazard ratio [HR] 0.37) and IpcPH (0.72 events/patient‐year; HR 0.45) patients. Participants without PH benefited most (0.26 events/patient‐year; HR 0.17, p = 0.04 vs. IpcPH/CpcPH patients). Quality of life and NYHA class improved significantly in all subgroups. Conclusions: Outpatients with NYHA class III symptoms with at least one HFH during 1 year pre‐implant benefitted significantly from PAP‐guided RPM during post‐implant follow‐up irrespective of presence or subtype of PH at baseline.Keywords
Funding Information
- Abbott Laboratories
This publication has 36 references indexed in Scilit:
- Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trialThe Lancet, 2016
- Left ventricular heart failure and pulmonary hypertensionEuropean Heart Journal, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Right Ventricular Function in Heart Failure With Preserved Ejection FractionCirculation, 2014
- The Global Health and Economic Burden of Hospitalizations for Heart FailureJACC, 2014
- Pulmonary Hypertension Due to Left Heart DiseasesJACC, 2013
- Pulmonary Hypertension Due to Left Heart DiseaseCirculation, 2012
- Pulmonary Hypertension in Heart Failure With Preserved Ejection FractionCirculation, 2011
- Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trialThe Lancet, 2011
- Heart Failure Care in the Outpatient Cardiology Practice SettingCirculation: Heart Failure, 2008